Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
News published by Insmed Incorporated concerning ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, administered with Lamira®, an optimized eFlow® Technology nebulizer.